ArticleScientific reports2025
Identification of biomarkers associated with M1 macrophages in the ST-segment elevation myocardial infarction through bioinformatics and machine learning approaches.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Timing-dependent anti-inflammatory effects of empagliflozin in monocyte-derived macrophages from post-myocardial infarct patients with type 2 diabetes.Cardiovascular diabetology · 2026Trial
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
ST-segment elevation myocardial infarction (STEMI) is considered a critical cardiac condition with a poor prognosis. Shortly after STEMI occurs, the increased number of circulating leukocytes including macrophages can lead to the accumulation of more cells in the myocardium, affecting the cardiac immune microenvironment. Identifying serum biomarkers associated with immune infiltration after STEMI is important for diagnosing and treating STEMI. In this work, we aimed to use integrated bioinformatics and machine learning methods to identify new biomarkers. First, candidate genes closely associated with M1 macrophage immune infiltration and STEMI were obtained using the limma package, the CIBERSORTx package, weighted gene coexpression network analysis (WGCNA), and protein‒protein interaction (PPI) networks from the GSE59867 dataset, which comprises peripheral blood mononuclear cell (PBMC) samples. The STEMI patients were subsequently stratified into subtypes using the ConsensusClusterPlus package. Furthermore, using machine learning methods, we identified AKT3, GJC2, HMGCL and RBM17 as the genes with the greatest potential to be associated with STEMI subtypes and with M1 macrophage infiltration during the acute phase of STEMI. Finally, the expression profile and diagnostic value of the four feature genes were validated in the GSE59867 and GSE62646 datasets and in 24 patients using real-time PCR. This study revealed logically and comprehensively that AKT3, GJC2, HMGCL and RBM17, which are derived from PBMCs, could enhance the accuracy of STEMI diagnosis and might provide effective treatment options for STEMI patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.